NasdaqHealth CarePharmaceutical PreparationsBETHESDA, MD

Gain Therapeutics, Inc. GANX

Ask your AI

Estimated market cap $46.31M44.53M shares, shares as of Oct 30, 2026CIK 1819411

Insider trades, 12 mo

—

No open-market trades

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

14.8% of shares · 6 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Gain Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Gain Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No recent insider purchases or sales for this company.

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

6.60M shares

35 funds report GANX. Values checked against market prices.

Funds own 21% of shares (Q2 2026)

50 funds hold the stock.

Q3 2026: 15% · 5,560 of ~8,900 funds reported so far

Q2 202511%
Q3 202512%
Q4 202522%
Q1 202619%
Q2 202621%
Q3 2026 (so far)15%

Q3 2026. 7 new, 6 added to, 8 trimmed, 23 exited since Q2 2026.

Top 13F holders
#
1	Marshall Wace, LLP 13F ↗	1.68M	$2.9M	-12.6%
2	Potomac Capital Management, Inc. 13F ↗	930,000	$1.6M	-1.7%
3	Jones Financial Companies LLLP 13F ↗	739,432	$1.3M	+21.5%
4	Cambridge Investment Research Advisors, Inc. 13F ↗	566,645	$980.0K	-50.2%
5	Vanguard Capital Management LLC 13F ↗	480,269	$830.9K	unchanged
6	Geode Capital Management, LLC 13F ↗	469,535	$813.0K	+3.5%
7	BlackRock, Inc. 13F ↗	268,321	$464.2K	-2.4%
8	UBS Group AG 13F ↗	241,483	$417.8K	+12.3%
9	Vanguard Fiduciary Trust Co 13F ↗	231,534	$400.6K	unchanged
10	State Street Corp 13F ↗	199,537	$345.2K	+26.7%

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds GANX, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Gain Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Gain Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q1 2021	12	—	1.01M	$15.0M
Q2 2021	14	+2	894,295	$8.9M
Q3 2021	14	0	892,629	$6.6M
Q4 2021	19	+5	1.08M	$5.8M
Q1 2022	16	-3	1.16M	$4.7M
Q2 2022	16	0	1.08M	$3.9M
Q3 2022	23	+7	1.21M	$4.0M
Q4 2022	21	-2	1.21M	$3.8M
Q1 2023	22	+1	1.15M	$5.5M
Q2 2023	24	+2	1.27M	$5.7M
Q3 2023	24	0	1.52M	$5.0M
Q4 2023	24	0	1.55M	$5.1M
Q1 2024	26	+2	1.87M	$7.1M
Q2 2024	28	+2	3.04M	$3.9M
Q3 2024	19	-9	1.68M	$9.8M
Q4 2024	25	+6	1.98M	$7.7M
Q1 2025	33	+8	2.81M	$8.2M
Q2 2025	35	+2	3.79M	$11.9M
Q3 2025	38	+3	4.37M	$7.7M
Q4 2025	48	+10	8.06M	$25.9M
Q1 2026	42	-6	8.19M	$15.8M
Q2 2026	50	+8	9.23M	$18.6M
Q3 2026	35	-15	6.60M	$11.4M

Each point is a quarter-end, from Q1 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (36269B105). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakesNone in 12 mo 8-K events4 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history2 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Gain Therapeutics, Inc.
Address: 4800 HAMPDEN LANE, SUITE 200, BETHESDA, MD 20814
Phone: (301) 500-1556
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company, emerging growth company
Incorporated in: DE
Listed as: GANX (Nasdaq)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.04−$0.04 (−3.70%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.9604 · High $1.41Nov 13, 2026

Aug 13, 2026Low $0.9604 · High $2.17Nov 13, 2026

Nov 13, 2025Low $0.9604 · High $4.18Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.